Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Poolbeg Pharma Ltd. ( (GB:POLB) ) just unveiled an announcement.
Poolbeg Pharma has announced a significant advancement in its POLB 001 Phase 2a trial, partnering with Accelerating Clinical Trials Limited to conduct the study and securing a supply of an approved bispecific antibody drug at no cost. The trial, led by Dr. Emma Searle at The Christie NHS Foundation Trust, aims to assess the safety and efficacy of POLB 001 in reducing Cytokine Release Syndrome in multiple myeloma patients. With interim data expected in 2026 and a cash runway extending into 2027, Poolbeg is well-positioned to enhance its market opportunity and potentially transform the delivery of cancer immunotherapies by making them safer and more accessible.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on transforming the cancer immunotherapy field. The company’s lead asset, POLB 001, aims to expand the administration of cancer immunotherapies from centralized specialist cancer centers into community hospitals by preventing Cytokine Release Syndrome (CRS), a life-threatening side effect. Poolbeg is also developing a patient-friendly therapy for obesity with an oral encapsulated GLP-1. The company targets large markets and addresses critical unmet medical needs.
Average Trading Volume: 1,391,417
Technical Sentiment Signal: Buy
Current Market Cap: £27.19M
For an in-depth examination of POLB stock, go to TipRanks’ Overview page.